Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 3/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL1837240 | 0.98 | CYP1A2 (0.63) | CYP1A2SIGMAR1HTTEPHX1NAAA | |
| Butylcyclohexane SCHEMBL1838223 | 0.94 | CYP1A2 (0.75) | CYP1A2SIGMAR1HTTLMNAMAPK1 | |
| Bicarbonate SCHEMBL5183166 | 0.90 | CYP1A2 (0.68) | CYP1A2SIGMAR1HTTPKMEPHX1 | |
| Bicarbonate SCHEMBL9562968 | 0.88 | CYP1A2 (0.65) | CYP1A2SIGMAR1HTTEPHX1NAAA | |
| Bicarbonate SCHEMBL4782415 | 0.88 | CYP1A2 (0.65) | CYP1A2SIGMAR1HTTEPHX1NAAA | |
| SCHEMBL8750956 | 0.88 | CYP1A2 (0.65) | CYP1A2SIGMAR1HTTPKMEPHX1 | |
| Propionic Acid SCHEMBL3879824 | 0.88 | CYP1A2 (0.65) | CYP1A2SIGMAR1HTTPKMEPHX1 | |
| Methyl Alcohol SCHEMBL8960609 | 0.87 | CYP1A2 (0.77) | CYP1A2SIGMAR1HTTLMNAMAPK1 | |
| SCHEMBL25394046 | 0.87 | CYP1A2 (0.85) | CYP1A2SIGMAR1EPHX1NAAA | |
| SCHEMBL7733130 | 0.87 | CYP1A2 (0.85) | CYP1A2SIGMAR1EPHX1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322504-B9 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2322504-B1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-9249090-B2 | N-substituted carbamic acid ester production method and isocyanate production method using the N-substituted carbamic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150038742-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-02-05 | — | — | US | disclosed |
| US-8884047-B2 | N-substituted carbamic acid ester production method and isocyanate production method using the N-substituted carbamic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2322504-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | Asahi Kasei Chemicals Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | CYP1A2 121/4885SIGMAR1 2888/4885HTT 423/4885 |
| US-20150038742-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | CYP1A2 121/4885SIGMAR1 2888/4885HTT 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.